[18F]FES (16-alfa-[18F]fluoroestradiol)

  • PET diagnostics for breast cancer quantifying the hormonal activity of tumor receptors
  • it is used only locally as an in-house PET radiopharmaceutical, yet it has no application in the area due to sufficient SPECT node diagnostics within the indication of the treatment

[18F]FET, INJ SOL (O-(2-[18F]fluorethyl)-L-tyrosine)

  • PET diagnostics for brain tumors
  • Compared to the routinely used [18F]Fludeoxyglucose, the ratio of radiopharmaceutical concentration tumor to normal tissue is significantly higher
  • Highly selective to tumor tissue, does not accumulate in inflammatory or necrotic tissues

[18F]FCH, INJ SOL ([18F]fluormethylcholine)

  • PET diagnostics for imaging primary and recurrent prostate cancer
  • Development of the technology of production and validation of quality control methods has been completed, preclinical evaluation has been completed

[18F]F-PSMA

  • PET diagnostics for imaging primary and recurrent prostate cancer
  • Highly selective for tumor tissue, not accumulating in inflammatory or necrotic tissues
  • Currently, the development of technologies for manufacture of the medicinal product is proceeding

[18F]FFMZ (2′-[18F]fluoroflumazenil)

  • PET diagnostics for Alzheimer disease and neurodegenerative brain diseases
  • It displays GABA (A) /benzendiazepine receptors and is therefore a suitable tool for localizing temporal epilepsy and displaying pulmonary ischemia and controlling chemotherapy
  • Compared to other methods such as magnetic resonance imaging, PET imaging with [18F]FDG and SPECT cerebral perfusion using [123I]IMZ, this radiopharmaceutical is significantly more beneficial